Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Breast Cancer Research and Treatment|January 25, 2005
The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER databaseJarrett Rosenberg, Yen Lin Chia, Sylvia Plevritis
Clinical Pharmacokinetics|March 12, 2019
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with AsthmaLi Yan, Bing Wang, Yen Lin Chia, et al.
Statistical Methods in Medical Research|December 14, 2004
Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustrationYen Lin Chia, Peter Salzman, Sylvia K Plevritis, et al.
Therapeutic Drug Monitoring|September 5, 2009
A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling timesYanfeng Wang, Yen Lin Chia, Jerry Nedelman, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2018
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumorsSherwin K B Sy, Yen Lin Chia, Toufigh Gordi, et al.
Clinical Pharmacology and Therapeutics|January 21, 2019
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic AsthmaYen Lin Chia, Li Yan, Binbing Yu, et al.
Clinical Pharmacology and Therapeutics|May 23, 2026
Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus NephritisJoachim Almquist, Yen Lin Chia, Raj Tummala, et al.
Rheumatology (Oxford, England)|February 25, 2021
Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosusYen Lin Chia, Linda Santiago, Bing Wang, et al.
Rheumatology (Oxford, England)|September 16, 2021
Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosusYen Lin Chia, Jianchun Zhang, Raj Tummala, et al.
British Journal of Clinical Pharmacology|June 12, 2024
Time-varying brentuximab vedotin pharmacokinetics and weight-based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6-11 yearsDaping Zhang, Zufei Zhang, Anthony Lee, et al.
Pageof 2